Brief: Moonlake Initiates Three New Clinical Trials And Expands Portfolio Of Indications For The Nanobody Sonelokimab

MoonLake Immunotherapeutics

08/01/2025 12:10

Jan 8 (Reuters) - MoonLake Immunotherapeutics  MLTX.O :
    * MOONLAKE INITIATES THREE NEW CLINICAL TRIALS AND FURTHER
EXPANDS
THE PORTFOLIO OF INDICATIONS FOR THE NANOBODY® SONELOKIMAB
    * MOONLAKE IMMUNOTHERAPEUTICS - PHASE 2 AND 3 DATA READ-OUTS
EXPECTED IN 2025 AND 2026
    * MOONLAKE IMMUNOTHERAPEUTICS - RUNNING SEVEN TRIALS IN 2025
    * MOONLAKE IMMUNOTHERAPEUTICS - TOPLINE PRIMARY ENDPOINT
READOUT
EXPECTED IN 2025
    * MOONLAKE IMMUNOTHERAPEUTICS - PRIMARY ENDPOINT OF S-OLARIS
TRIAL
IS CHANGE IN 18F-NAF UPTAKE

Source text:  ID:nGNX8kGyJ9 
Further company coverage:  MLTX.O 

 ((Reuters.Brief@thomsonreuters.com))